Utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor
Purpose The purpose of this study was to find useful imaging features on non-contrast-enhanced magnetic resonance imaging (MRI) that can divide patients with thymic epithelial tumor (TET) into clinical stage I-II and III-IV groups under assumption that contrast media are contraindicated. Materials a...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Kuhara, Asako [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The Author(s) 2022 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Radiation medicine - Tokyo : Springer, 1999, 41(2022), 3 vom: 14. Nov., Seite 302-311 |
|---|---|
| Übergeordnetes Werk: |
volume:41 ; year:2022 ; number:3 ; day:14 ; month:11 ; pages:302-311 |
| Links: |
|---|
| DOI / URN: |
10.1007/s11604-022-01358-y |
|---|
| Katalog-ID: |
SPR049506099 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR049506099 | ||
| 003 | DE-627 | ||
| 005 | 20230510064340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230301s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11604-022-01358-y |2 doi | |
| 035 | |a (DE-627)SPR049506099 | ||
| 035 | |a (SPR)s11604-022-01358-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kuhara, Asako |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Purpose The purpose of this study was to find useful imaging features on non-contrast-enhanced magnetic resonance imaging (MRI) that can divide patients with thymic epithelial tumor (TET) into clinical stage I-II and III-IV groups under assumption that contrast media are contraindicated. Materials and methods This retrospective study included 106 patients (median age, 60 years; range, 27–82 years; 62 women) with surgically resected TET who underwent MRI between August 1986 and July 2015. All cases were classified according to the 2015 WHO classification and staged using the eighth edition of the TNM system. Two radiologists independently evaluated 14 categories of MRI findings; the findings in patients with stage I-II were compared with those of patients with stage III-IV using a logistic regression model. Disease-specific survival associated with significant findings was calculated using the Kaplan–Meier method. Results Univariate analysis showed that stage III-IV patients were more likely to have tumors with an irregular contour, heterogeneity on T1WI, low-signal intensity on T2WI, irregular border with lung, findings of great vessel invasion (GVI) (hereafter, GVI sign), pericardial thickening/nodule, and lymphadenopathy (all, P < 0.01). On multivariable analysis, only two findings, irregular border between tumor and lung (odds ratio [OR], 272.8; 95% CI 26.6–2794.1; P < 0.001) and positive GVI sign (OR, 49.3; 95% CI 4.5–539.8; P = 0.001) remained statistically significant. Patients with one or both features had significantly worse survival (log-rank test, P < 0.001). Conclusion For patients with TET who are unable to receive contrast for preoperative staging, the two image findings of an irregular border between tumor and lung and the positive GVI sign on non-contrast-enhanced MRI could be helpful in determining stage III-IV disease which is associated with a worse survival. | ||
| 650 | 4 | |a Thymic epithelial tumor |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Magnetic resonance imaging |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Contrast media |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a World Health Organization Classification |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a TNM stage |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Sumi, Akiko |4 aut | |
| 700 | 1 | |a Chikasue, Tomonori |4 aut | |
| 700 | 1 | |a Kawaguchi, Atsushi |4 aut | |
| 700 | 1 | |a Tanoue, Shuichi |4 aut | |
| 700 | 1 | |a Nagata, Shuji |4 aut | |
| 700 | 1 | |a Koganemaru, Masamichi |4 aut | |
| 700 | 1 | |a Abe, Toshi |4 aut | |
| 700 | 1 | |a Kashihara, Masaki |4 aut | |
| 700 | 1 | |a Mitsuoka, Masahiro |4 aut | |
| 700 | 1 | |a Ishii, Hidenobu |4 aut | |
| 700 | 1 | |a Ohshima, Koichi |4 aut | |
| 700 | 1 | |a Leung, Ann N. C. |4 aut | |
| 700 | 1 | |a Fujimoto, Kiminori |0 (orcid)0000-0001-8681-7588 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Radiation medicine |d Tokyo : Springer, 1999 |g 41(2022), 3 vom: 14. Nov., Seite 302-311 |w (DE-627)368312305 |w (DE-600)2117284-5 |x 1862-5274 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2022 |g number:3 |g day:14 |g month:11 |g pages:302-311 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11604-022-01358-y |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_138 | ||
| 912 | |a GBV_ILN_152 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_250 | ||
| 912 | |a GBV_ILN_281 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_702 | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2022 |e 3 |b 14 |c 11 |h 302-311 | ||
| author_variant |
a k ak a s as t c tc a k ak s t st s n sn m k mk t a ta m k mk m m mm h i hi k o ko a n c l anc ancl k f kf |
|---|---|
| matchkey_str |
article:18625274:2022----::tltonnotatnacdantceoaciaignrdcigroeaielncltgadrgoii |
| hierarchy_sort_str |
2022 |
| publishDate |
2022 |
| allfields |
10.1007/s11604-022-01358-y doi (DE-627)SPR049506099 (SPR)s11604-022-01358-y-e DE-627 ger DE-627 rakwb eng Kuhara, Asako verfasserin aut Utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022 Purpose The purpose of this study was to find useful imaging features on non-contrast-enhanced magnetic resonance imaging (MRI) that can divide patients with thymic epithelial tumor (TET) into clinical stage I-II and III-IV groups under assumption that contrast media are contraindicated. Materials and methods This retrospective study included 106 patients (median age, 60 years; range, 27–82 years; 62 women) with surgically resected TET who underwent MRI between August 1986 and July 2015. All cases were classified according to the 2015 WHO classification and staged using the eighth edition of the TNM system. Two radiologists independently evaluated 14 categories of MRI findings; the findings in patients with stage I-II were compared with those of patients with stage III-IV using a logistic regression model. Disease-specific survival associated with significant findings was calculated using the Kaplan–Meier method. Results Univariate analysis showed that stage III-IV patients were more likely to have tumors with an irregular contour, heterogeneity on T1WI, low-signal intensity on T2WI, irregular border with lung, findings of great vessel invasion (GVI) (hereafter, GVI sign), pericardial thickening/nodule, and lymphadenopathy (all, P < 0.01). On multivariable analysis, only two findings, irregular border between tumor and lung (odds ratio [OR], 272.8; 95% CI 26.6–2794.1; P < 0.001) and positive GVI sign (OR, 49.3; 95% CI 4.5–539.8; P = 0.001) remained statistically significant. Patients with one or both features had significantly worse survival (log-rank test, P < 0.001). Conclusion For patients with TET who are unable to receive contrast for preoperative staging, the two image findings of an irregular border between tumor and lung and the positive GVI sign on non-contrast-enhanced MRI could be helpful in determining stage III-IV disease which is associated with a worse survival. Thymic epithelial tumor (dpeaa)DE-He213 Magnetic resonance imaging (dpeaa)DE-He213 Contrast media (dpeaa)DE-He213 World Health Organization Classification (dpeaa)DE-He213 TNM stage (dpeaa)DE-He213 Sumi, Akiko aut Chikasue, Tomonori aut Kawaguchi, Atsushi aut Tanoue, Shuichi aut Nagata, Shuji aut Koganemaru, Masamichi aut Abe, Toshi aut Kashihara, Masaki aut Mitsuoka, Masahiro aut Ishii, Hidenobu aut Ohshima, Koichi aut Leung, Ann N. C. aut Fujimoto, Kiminori (orcid)0000-0001-8681-7588 aut Enthalten in Radiation medicine Tokyo : Springer, 1999 41(2022), 3 vom: 14. Nov., Seite 302-311 (DE-627)368312305 (DE-600)2117284-5 1862-5274 nnns volume:41 year:2022 number:3 day:14 month:11 pages:302-311 https://dx.doi.org/10.1007/s11604-022-01358-y kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 41 2022 3 14 11 302-311 |
| spelling |
10.1007/s11604-022-01358-y doi (DE-627)SPR049506099 (SPR)s11604-022-01358-y-e DE-627 ger DE-627 rakwb eng Kuhara, Asako verfasserin aut Utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022 Purpose The purpose of this study was to find useful imaging features on non-contrast-enhanced magnetic resonance imaging (MRI) that can divide patients with thymic epithelial tumor (TET) into clinical stage I-II and III-IV groups under assumption that contrast media are contraindicated. Materials and methods This retrospective study included 106 patients (median age, 60 years; range, 27–82 years; 62 women) with surgically resected TET who underwent MRI between August 1986 and July 2015. All cases were classified according to the 2015 WHO classification and staged using the eighth edition of the TNM system. Two radiologists independently evaluated 14 categories of MRI findings; the findings in patients with stage I-II were compared with those of patients with stage III-IV using a logistic regression model. Disease-specific survival associated with significant findings was calculated using the Kaplan–Meier method. Results Univariate analysis showed that stage III-IV patients were more likely to have tumors with an irregular contour, heterogeneity on T1WI, low-signal intensity on T2WI, irregular border with lung, findings of great vessel invasion (GVI) (hereafter, GVI sign), pericardial thickening/nodule, and lymphadenopathy (all, P < 0.01). On multivariable analysis, only two findings, irregular border between tumor and lung (odds ratio [OR], 272.8; 95% CI 26.6–2794.1; P < 0.001) and positive GVI sign (OR, 49.3; 95% CI 4.5–539.8; P = 0.001) remained statistically significant. Patients with one or both features had significantly worse survival (log-rank test, P < 0.001). Conclusion For patients with TET who are unable to receive contrast for preoperative staging, the two image findings of an irregular border between tumor and lung and the positive GVI sign on non-contrast-enhanced MRI could be helpful in determining stage III-IV disease which is associated with a worse survival. Thymic epithelial tumor (dpeaa)DE-He213 Magnetic resonance imaging (dpeaa)DE-He213 Contrast media (dpeaa)DE-He213 World Health Organization Classification (dpeaa)DE-He213 TNM stage (dpeaa)DE-He213 Sumi, Akiko aut Chikasue, Tomonori aut Kawaguchi, Atsushi aut Tanoue, Shuichi aut Nagata, Shuji aut Koganemaru, Masamichi aut Abe, Toshi aut Kashihara, Masaki aut Mitsuoka, Masahiro aut Ishii, Hidenobu aut Ohshima, Koichi aut Leung, Ann N. C. aut Fujimoto, Kiminori (orcid)0000-0001-8681-7588 aut Enthalten in Radiation medicine Tokyo : Springer, 1999 41(2022), 3 vom: 14. Nov., Seite 302-311 (DE-627)368312305 (DE-600)2117284-5 1862-5274 nnns volume:41 year:2022 number:3 day:14 month:11 pages:302-311 https://dx.doi.org/10.1007/s11604-022-01358-y kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 41 2022 3 14 11 302-311 |
| allfields_unstemmed |
10.1007/s11604-022-01358-y doi (DE-627)SPR049506099 (SPR)s11604-022-01358-y-e DE-627 ger DE-627 rakwb eng Kuhara, Asako verfasserin aut Utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022 Purpose The purpose of this study was to find useful imaging features on non-contrast-enhanced magnetic resonance imaging (MRI) that can divide patients with thymic epithelial tumor (TET) into clinical stage I-II and III-IV groups under assumption that contrast media are contraindicated. Materials and methods This retrospective study included 106 patients (median age, 60 years; range, 27–82 years; 62 women) with surgically resected TET who underwent MRI between August 1986 and July 2015. All cases were classified according to the 2015 WHO classification and staged using the eighth edition of the TNM system. Two radiologists independently evaluated 14 categories of MRI findings; the findings in patients with stage I-II were compared with those of patients with stage III-IV using a logistic regression model. Disease-specific survival associated with significant findings was calculated using the Kaplan–Meier method. Results Univariate analysis showed that stage III-IV patients were more likely to have tumors with an irregular contour, heterogeneity on T1WI, low-signal intensity on T2WI, irregular border with lung, findings of great vessel invasion (GVI) (hereafter, GVI sign), pericardial thickening/nodule, and lymphadenopathy (all, P < 0.01). On multivariable analysis, only two findings, irregular border between tumor and lung (odds ratio [OR], 272.8; 95% CI 26.6–2794.1; P < 0.001) and positive GVI sign (OR, 49.3; 95% CI 4.5–539.8; P = 0.001) remained statistically significant. Patients with one or both features had significantly worse survival (log-rank test, P < 0.001). Conclusion For patients with TET who are unable to receive contrast for preoperative staging, the two image findings of an irregular border between tumor and lung and the positive GVI sign on non-contrast-enhanced MRI could be helpful in determining stage III-IV disease which is associated with a worse survival. Thymic epithelial tumor (dpeaa)DE-He213 Magnetic resonance imaging (dpeaa)DE-He213 Contrast media (dpeaa)DE-He213 World Health Organization Classification (dpeaa)DE-He213 TNM stage (dpeaa)DE-He213 Sumi, Akiko aut Chikasue, Tomonori aut Kawaguchi, Atsushi aut Tanoue, Shuichi aut Nagata, Shuji aut Koganemaru, Masamichi aut Abe, Toshi aut Kashihara, Masaki aut Mitsuoka, Masahiro aut Ishii, Hidenobu aut Ohshima, Koichi aut Leung, Ann N. C. aut Fujimoto, Kiminori (orcid)0000-0001-8681-7588 aut Enthalten in Radiation medicine Tokyo : Springer, 1999 41(2022), 3 vom: 14. Nov., Seite 302-311 (DE-627)368312305 (DE-600)2117284-5 1862-5274 nnns volume:41 year:2022 number:3 day:14 month:11 pages:302-311 https://dx.doi.org/10.1007/s11604-022-01358-y kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 41 2022 3 14 11 302-311 |
| allfieldsGer |
10.1007/s11604-022-01358-y doi (DE-627)SPR049506099 (SPR)s11604-022-01358-y-e DE-627 ger DE-627 rakwb eng Kuhara, Asako verfasserin aut Utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022 Purpose The purpose of this study was to find useful imaging features on non-contrast-enhanced magnetic resonance imaging (MRI) that can divide patients with thymic epithelial tumor (TET) into clinical stage I-II and III-IV groups under assumption that contrast media are contraindicated. Materials and methods This retrospective study included 106 patients (median age, 60 years; range, 27–82 years; 62 women) with surgically resected TET who underwent MRI between August 1986 and July 2015. All cases were classified according to the 2015 WHO classification and staged using the eighth edition of the TNM system. Two radiologists independently evaluated 14 categories of MRI findings; the findings in patients with stage I-II were compared with those of patients with stage III-IV using a logistic regression model. Disease-specific survival associated with significant findings was calculated using the Kaplan–Meier method. Results Univariate analysis showed that stage III-IV patients were more likely to have tumors with an irregular contour, heterogeneity on T1WI, low-signal intensity on T2WI, irregular border with lung, findings of great vessel invasion (GVI) (hereafter, GVI sign), pericardial thickening/nodule, and lymphadenopathy (all, P < 0.01). On multivariable analysis, only two findings, irregular border between tumor and lung (odds ratio [OR], 272.8; 95% CI 26.6–2794.1; P < 0.001) and positive GVI sign (OR, 49.3; 95% CI 4.5–539.8; P = 0.001) remained statistically significant. Patients with one or both features had significantly worse survival (log-rank test, P < 0.001). Conclusion For patients with TET who are unable to receive contrast for preoperative staging, the two image findings of an irregular border between tumor and lung and the positive GVI sign on non-contrast-enhanced MRI could be helpful in determining stage III-IV disease which is associated with a worse survival. Thymic epithelial tumor (dpeaa)DE-He213 Magnetic resonance imaging (dpeaa)DE-He213 Contrast media (dpeaa)DE-He213 World Health Organization Classification (dpeaa)DE-He213 TNM stage (dpeaa)DE-He213 Sumi, Akiko aut Chikasue, Tomonori aut Kawaguchi, Atsushi aut Tanoue, Shuichi aut Nagata, Shuji aut Koganemaru, Masamichi aut Abe, Toshi aut Kashihara, Masaki aut Mitsuoka, Masahiro aut Ishii, Hidenobu aut Ohshima, Koichi aut Leung, Ann N. C. aut Fujimoto, Kiminori (orcid)0000-0001-8681-7588 aut Enthalten in Radiation medicine Tokyo : Springer, 1999 41(2022), 3 vom: 14. Nov., Seite 302-311 (DE-627)368312305 (DE-600)2117284-5 1862-5274 nnns volume:41 year:2022 number:3 day:14 month:11 pages:302-311 https://dx.doi.org/10.1007/s11604-022-01358-y kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 41 2022 3 14 11 302-311 |
| allfieldsSound |
10.1007/s11604-022-01358-y doi (DE-627)SPR049506099 (SPR)s11604-022-01358-y-e DE-627 ger DE-627 rakwb eng Kuhara, Asako verfasserin aut Utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2022 Purpose The purpose of this study was to find useful imaging features on non-contrast-enhanced magnetic resonance imaging (MRI) that can divide patients with thymic epithelial tumor (TET) into clinical stage I-II and III-IV groups under assumption that contrast media are contraindicated. Materials and methods This retrospective study included 106 patients (median age, 60 years; range, 27–82 years; 62 women) with surgically resected TET who underwent MRI between August 1986 and July 2015. All cases were classified according to the 2015 WHO classification and staged using the eighth edition of the TNM system. Two radiologists independently evaluated 14 categories of MRI findings; the findings in patients with stage I-II were compared with those of patients with stage III-IV using a logistic regression model. Disease-specific survival associated with significant findings was calculated using the Kaplan–Meier method. Results Univariate analysis showed that stage III-IV patients were more likely to have tumors with an irregular contour, heterogeneity on T1WI, low-signal intensity on T2WI, irregular border with lung, findings of great vessel invasion (GVI) (hereafter, GVI sign), pericardial thickening/nodule, and lymphadenopathy (all, P < 0.01). On multivariable analysis, only two findings, irregular border between tumor and lung (odds ratio [OR], 272.8; 95% CI 26.6–2794.1; P < 0.001) and positive GVI sign (OR, 49.3; 95% CI 4.5–539.8; P = 0.001) remained statistically significant. Patients with one or both features had significantly worse survival (log-rank test, P < 0.001). Conclusion For patients with TET who are unable to receive contrast for preoperative staging, the two image findings of an irregular border between tumor and lung and the positive GVI sign on non-contrast-enhanced MRI could be helpful in determining stage III-IV disease which is associated with a worse survival. Thymic epithelial tumor (dpeaa)DE-He213 Magnetic resonance imaging (dpeaa)DE-He213 Contrast media (dpeaa)DE-He213 World Health Organization Classification (dpeaa)DE-He213 TNM stage (dpeaa)DE-He213 Sumi, Akiko aut Chikasue, Tomonori aut Kawaguchi, Atsushi aut Tanoue, Shuichi aut Nagata, Shuji aut Koganemaru, Masamichi aut Abe, Toshi aut Kashihara, Masaki aut Mitsuoka, Masahiro aut Ishii, Hidenobu aut Ohshima, Koichi aut Leung, Ann N. C. aut Fujimoto, Kiminori (orcid)0000-0001-8681-7588 aut Enthalten in Radiation medicine Tokyo : Springer, 1999 41(2022), 3 vom: 14. Nov., Seite 302-311 (DE-627)368312305 (DE-600)2117284-5 1862-5274 nnns volume:41 year:2022 number:3 day:14 month:11 pages:302-311 https://dx.doi.org/10.1007/s11604-022-01358-y kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 41 2022 3 14 11 302-311 |
| language |
English |
| source |
Enthalten in Radiation medicine 41(2022), 3 vom: 14. Nov., Seite 302-311 volume:41 year:2022 number:3 day:14 month:11 pages:302-311 |
| sourceStr |
Enthalten in Radiation medicine 41(2022), 3 vom: 14. Nov., Seite 302-311 volume:41 year:2022 number:3 day:14 month:11 pages:302-311 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Thymic epithelial tumor Magnetic resonance imaging Contrast media World Health Organization Classification TNM stage |
| isfreeaccess_bool |
true |
| container_title |
Radiation medicine |
| authorswithroles_txt_mv |
Kuhara, Asako @@aut@@ Sumi, Akiko @@aut@@ Chikasue, Tomonori @@aut@@ Kawaguchi, Atsushi @@aut@@ Tanoue, Shuichi @@aut@@ Nagata, Shuji @@aut@@ Koganemaru, Masamichi @@aut@@ Abe, Toshi @@aut@@ Kashihara, Masaki @@aut@@ Mitsuoka, Masahiro @@aut@@ Ishii, Hidenobu @@aut@@ Ohshima, Koichi @@aut@@ Leung, Ann N. C. @@aut@@ Fujimoto, Kiminori @@aut@@ |
| publishDateDaySort_date |
2022-11-14T00:00:00Z |
| hierarchy_top_id |
368312305 |
| id |
SPR049506099 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR049506099</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230510064340.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230301s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11604-022-01358-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR049506099</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s11604-022-01358-y-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kuhara, Asako</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2022</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose The purpose of this study was to find useful imaging features on non-contrast-enhanced magnetic resonance imaging (MRI) that can divide patients with thymic epithelial tumor (TET) into clinical stage I-II and III-IV groups under assumption that contrast media are contraindicated. Materials and methods This retrospective study included 106 patients (median age, 60 years; range, 27–82 years; 62 women) with surgically resected TET who underwent MRI between August 1986 and July 2015. All cases were classified according to the 2015 WHO classification and staged using the eighth edition of the TNM system. Two radiologists independently evaluated 14 categories of MRI findings; the findings in patients with stage I-II were compared with those of patients with stage III-IV using a logistic regression model. Disease-specific survival associated with significant findings was calculated using the Kaplan–Meier method. Results Univariate analysis showed that stage III-IV patients were more likely to have tumors with an irregular contour, heterogeneity on T1WI, low-signal intensity on T2WI, irregular border with lung, findings of great vessel invasion (GVI) (hereafter, GVI sign), pericardial thickening/nodule, and lymphadenopathy (all, P < 0.01). On multivariable analysis, only two findings, irregular border between tumor and lung (odds ratio [OR], 272.8; 95% CI 26.6–2794.1; P < 0.001) and positive GVI sign (OR, 49.3; 95% CI 4.5–539.8; P = 0.001) remained statistically significant. Patients with one or both features had significantly worse survival (log-rank test, P < 0.001). Conclusion For patients with TET who are unable to receive contrast for preoperative staging, the two image findings of an irregular border between tumor and lung and the positive GVI sign on non-contrast-enhanced MRI could be helpful in determining stage III-IV disease which is associated with a worse survival.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Thymic epithelial tumor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Magnetic resonance imaging</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Contrast media</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">World Health Organization Classification</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">TNM stage</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sumi, Akiko</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chikasue, Tomonori</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kawaguchi, Atsushi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tanoue, Shuichi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nagata, Shuji</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Koganemaru, Masamichi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Abe, Toshi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kashihara, Masaki</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mitsuoka, Masahiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ishii, Hidenobu</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohshima, Koichi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leung, Ann N. C.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fujimoto, Kiminori</subfield><subfield code="0">(orcid)0000-0001-8681-7588</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Radiation medicine</subfield><subfield code="d">Tokyo : Springer, 1999</subfield><subfield code="g">41(2022), 3 vom: 14. Nov., Seite 302-311</subfield><subfield code="w">(DE-627)368312305</subfield><subfield code="w">(DE-600)2117284-5</subfield><subfield code="x">1862-5274</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:41</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:3</subfield><subfield code="g">day:14</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:302-311</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s11604-022-01358-y</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">41</subfield><subfield code="j">2022</subfield><subfield code="e">3</subfield><subfield code="b">14</subfield><subfield code="c">11</subfield><subfield code="h">302-311</subfield></datafield></record></collection>
|
| author |
Kuhara, Asako |
| spellingShingle |
Kuhara, Asako misc Thymic epithelial tumor misc Magnetic resonance imaging misc Contrast media misc World Health Organization Classification misc TNM stage Utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor |
| authorStr |
Kuhara, Asako |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)368312305 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1862-5274 |
| topic_title |
Utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor Thymic epithelial tumor (dpeaa)DE-He213 Magnetic resonance imaging (dpeaa)DE-He213 Contrast media (dpeaa)DE-He213 World Health Organization Classification (dpeaa)DE-He213 TNM stage (dpeaa)DE-He213 |
| topic |
misc Thymic epithelial tumor misc Magnetic resonance imaging misc Contrast media misc World Health Organization Classification misc TNM stage |
| topic_unstemmed |
misc Thymic epithelial tumor misc Magnetic resonance imaging misc Contrast media misc World Health Organization Classification misc TNM stage |
| topic_browse |
misc Thymic epithelial tumor misc Magnetic resonance imaging misc Contrast media misc World Health Organization Classification misc TNM stage |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Radiation medicine |
| hierarchy_parent_id |
368312305 |
| hierarchy_top_title |
Radiation medicine |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)368312305 (DE-600)2117284-5 |
| title |
Utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor |
| ctrlnum |
(DE-627)SPR049506099 (SPR)s11604-022-01358-y-e |
| title_full |
Utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor |
| author_sort |
Kuhara, Asako |
| journal |
Radiation medicine |
| journalStr |
Radiation medicine |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
txt |
| container_start_page |
302 |
| author_browse |
Kuhara, Asako Sumi, Akiko Chikasue, Tomonori Kawaguchi, Atsushi Tanoue, Shuichi Nagata, Shuji Koganemaru, Masamichi Abe, Toshi Kashihara, Masaki Mitsuoka, Masahiro Ishii, Hidenobu Ohshima, Koichi Leung, Ann N. C. Fujimoto, Kiminori |
| container_volume |
41 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Kuhara, Asako |
| doi_str_mv |
10.1007/s11604-022-01358-y |
| normlink |
(ORCID)0000-0001-8681-7588 |
| normlink_prefix_str_mv |
(orcid)0000-0001-8681-7588 |
| title_sort |
utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor |
| title_auth |
Utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor |
| abstract |
Purpose The purpose of this study was to find useful imaging features on non-contrast-enhanced magnetic resonance imaging (MRI) that can divide patients with thymic epithelial tumor (TET) into clinical stage I-II and III-IV groups under assumption that contrast media are contraindicated. Materials and methods This retrospective study included 106 patients (median age, 60 years; range, 27–82 years; 62 women) with surgically resected TET who underwent MRI between August 1986 and July 2015. All cases were classified according to the 2015 WHO classification and staged using the eighth edition of the TNM system. Two radiologists independently evaluated 14 categories of MRI findings; the findings in patients with stage I-II were compared with those of patients with stage III-IV using a logistic regression model. Disease-specific survival associated with significant findings was calculated using the Kaplan–Meier method. Results Univariate analysis showed that stage III-IV patients were more likely to have tumors with an irregular contour, heterogeneity on T1WI, low-signal intensity on T2WI, irregular border with lung, findings of great vessel invasion (GVI) (hereafter, GVI sign), pericardial thickening/nodule, and lymphadenopathy (all, P < 0.01). On multivariable analysis, only two findings, irregular border between tumor and lung (odds ratio [OR], 272.8; 95% CI 26.6–2794.1; P < 0.001) and positive GVI sign (OR, 49.3; 95% CI 4.5–539.8; P = 0.001) remained statistically significant. Patients with one or both features had significantly worse survival (log-rank test, P < 0.001). Conclusion For patients with TET who are unable to receive contrast for preoperative staging, the two image findings of an irregular border between tumor and lung and the positive GVI sign on non-contrast-enhanced MRI could be helpful in determining stage III-IV disease which is associated with a worse survival. © The Author(s) 2022 |
| abstractGer |
Purpose The purpose of this study was to find useful imaging features on non-contrast-enhanced magnetic resonance imaging (MRI) that can divide patients with thymic epithelial tumor (TET) into clinical stage I-II and III-IV groups under assumption that contrast media are contraindicated. Materials and methods This retrospective study included 106 patients (median age, 60 years; range, 27–82 years; 62 women) with surgically resected TET who underwent MRI between August 1986 and July 2015. All cases were classified according to the 2015 WHO classification and staged using the eighth edition of the TNM system. Two radiologists independently evaluated 14 categories of MRI findings; the findings in patients with stage I-II were compared with those of patients with stage III-IV using a logistic regression model. Disease-specific survival associated with significant findings was calculated using the Kaplan–Meier method. Results Univariate analysis showed that stage III-IV patients were more likely to have tumors with an irregular contour, heterogeneity on T1WI, low-signal intensity on T2WI, irregular border with lung, findings of great vessel invasion (GVI) (hereafter, GVI sign), pericardial thickening/nodule, and lymphadenopathy (all, P < 0.01). On multivariable analysis, only two findings, irregular border between tumor and lung (odds ratio [OR], 272.8; 95% CI 26.6–2794.1; P < 0.001) and positive GVI sign (OR, 49.3; 95% CI 4.5–539.8; P = 0.001) remained statistically significant. Patients with one or both features had significantly worse survival (log-rank test, P < 0.001). Conclusion For patients with TET who are unable to receive contrast for preoperative staging, the two image findings of an irregular border between tumor and lung and the positive GVI sign on non-contrast-enhanced MRI could be helpful in determining stage III-IV disease which is associated with a worse survival. © The Author(s) 2022 |
| abstract_unstemmed |
Purpose The purpose of this study was to find useful imaging features on non-contrast-enhanced magnetic resonance imaging (MRI) that can divide patients with thymic epithelial tumor (TET) into clinical stage I-II and III-IV groups under assumption that contrast media are contraindicated. Materials and methods This retrospective study included 106 patients (median age, 60 years; range, 27–82 years; 62 women) with surgically resected TET who underwent MRI between August 1986 and July 2015. All cases were classified according to the 2015 WHO classification and staged using the eighth edition of the TNM system. Two radiologists independently evaluated 14 categories of MRI findings; the findings in patients with stage I-II were compared with those of patients with stage III-IV using a logistic regression model. Disease-specific survival associated with significant findings was calculated using the Kaplan–Meier method. Results Univariate analysis showed that stage III-IV patients were more likely to have tumors with an irregular contour, heterogeneity on T1WI, low-signal intensity on T2WI, irregular border with lung, findings of great vessel invasion (GVI) (hereafter, GVI sign), pericardial thickening/nodule, and lymphadenopathy (all, P < 0.01). On multivariable analysis, only two findings, irregular border between tumor and lung (odds ratio [OR], 272.8; 95% CI 26.6–2794.1; P < 0.001) and positive GVI sign (OR, 49.3; 95% CI 4.5–539.8; P = 0.001) remained statistically significant. Patients with one or both features had significantly worse survival (log-rank test, P < 0.001). Conclusion For patients with TET who are unable to receive contrast for preoperative staging, the two image findings of an irregular border between tumor and lung and the positive GVI sign on non-contrast-enhanced MRI could be helpful in determining stage III-IV disease which is associated with a worse survival. © The Author(s) 2022 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 |
| container_issue |
3 |
| title_short |
Utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor |
| url |
https://dx.doi.org/10.1007/s11604-022-01358-y |
| remote_bool |
true |
| author2 |
Sumi, Akiko Chikasue, Tomonori Kawaguchi, Atsushi Tanoue, Shuichi Nagata, Shuji Koganemaru, Masamichi Abe, Toshi Kashihara, Masaki Mitsuoka, Masahiro Ishii, Hidenobu Ohshima, Koichi Leung, Ann N. C. Fujimoto, Kiminori |
| author2Str |
Sumi, Akiko Chikasue, Tomonori Kawaguchi, Atsushi Tanoue, Shuichi Nagata, Shuji Koganemaru, Masamichi Abe, Toshi Kashihara, Masaki Mitsuoka, Masahiro Ishii, Hidenobu Ohshima, Koichi Leung, Ann N. C. Fujimoto, Kiminori |
| ppnlink |
368312305 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s11604-022-01358-y |
| up_date |
2024-07-04T01:05:58.239Z |
| _version_ |
1803608557607714816 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR049506099</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230510064340.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230301s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11604-022-01358-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR049506099</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s11604-022-01358-y-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kuhara, Asako</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Utility of non-contrast-enhanced magnetic resonance imaging in predicting preoperative clinical stage and prognosis in patients with thymic epithelial tumor</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2022</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose The purpose of this study was to find useful imaging features on non-contrast-enhanced magnetic resonance imaging (MRI) that can divide patients with thymic epithelial tumor (TET) into clinical stage I-II and III-IV groups under assumption that contrast media are contraindicated. Materials and methods This retrospective study included 106 patients (median age, 60 years; range, 27–82 years; 62 women) with surgically resected TET who underwent MRI between August 1986 and July 2015. All cases were classified according to the 2015 WHO classification and staged using the eighth edition of the TNM system. Two radiologists independently evaluated 14 categories of MRI findings; the findings in patients with stage I-II were compared with those of patients with stage III-IV using a logistic regression model. Disease-specific survival associated with significant findings was calculated using the Kaplan–Meier method. Results Univariate analysis showed that stage III-IV patients were more likely to have tumors with an irregular contour, heterogeneity on T1WI, low-signal intensity on T2WI, irregular border with lung, findings of great vessel invasion (GVI) (hereafter, GVI sign), pericardial thickening/nodule, and lymphadenopathy (all, P < 0.01). On multivariable analysis, only two findings, irregular border between tumor and lung (odds ratio [OR], 272.8; 95% CI 26.6–2794.1; P < 0.001) and positive GVI sign (OR, 49.3; 95% CI 4.5–539.8; P = 0.001) remained statistically significant. Patients with one or both features had significantly worse survival (log-rank test, P < 0.001). Conclusion For patients with TET who are unable to receive contrast for preoperative staging, the two image findings of an irregular border between tumor and lung and the positive GVI sign on non-contrast-enhanced MRI could be helpful in determining stage III-IV disease which is associated with a worse survival.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Thymic epithelial tumor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Magnetic resonance imaging</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Contrast media</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">World Health Organization Classification</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">TNM stage</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sumi, Akiko</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chikasue, Tomonori</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kawaguchi, Atsushi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tanoue, Shuichi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nagata, Shuji</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Koganemaru, Masamichi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Abe, Toshi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kashihara, Masaki</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mitsuoka, Masahiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ishii, Hidenobu</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohshima, Koichi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leung, Ann N. C.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fujimoto, Kiminori</subfield><subfield code="0">(orcid)0000-0001-8681-7588</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Radiation medicine</subfield><subfield code="d">Tokyo : Springer, 1999</subfield><subfield code="g">41(2022), 3 vom: 14. Nov., Seite 302-311</subfield><subfield code="w">(DE-627)368312305</subfield><subfield code="w">(DE-600)2117284-5</subfield><subfield code="x">1862-5274</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:41</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:3</subfield><subfield code="g">day:14</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:302-311</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s11604-022-01358-y</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">41</subfield><subfield code="j">2022</subfield><subfield code="e">3</subfield><subfield code="b">14</subfield><subfield code="c">11</subfield><subfield code="h">302-311</subfield></datafield></record></collection>
|
| score |
7.399781 |